Formycon Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Stefan Glombitza

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	7.6yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.9yrs
Promedio de permanencia en la Junta Directiva	9.2yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Stefan Glombitza (58 yo)

7.6yrs

Permanencia

Dr. Stefan Glombitza has been Member of Executive Board at Formycon AG since October 1, 2016 and is Chief Executive Officer from July 01, 2022. Dr. Glombitza served as Chief Operating Officer of Formycon...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stefan Glombitza	CEO & Member of Executive Board	7.6yrs	sin datos	sin datos
Friedrich-Wilhelm Steinweg	Co-Founder	no data	sin datos	sin datos
Nicolas Combe	Co-Founder	no data	sin datos	sin datos
Enno Spillner	CFO & Member of Management Board	1.1yrs	sin datos	sin datos
Andreas Seidl	Chief Scientific Officer & Member of Executive Board	1.8yrs	sin datos	sin datos
Nicola Mikulcik	Chief Business Officer & Member of Executive Board	1.9yrs	sin datos	sin datos
Sabrina Muller	Director of Investor Relations & Corporate Communications	no data	sin datos	sin datos

1.9yrs

Permanencia media

52.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0W4N no se considera experimentado ( 1.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Bernhard Hampl	Member of Advisory Board	10.2yrs	sin datos	sin datos
Gerhard Schaefer	Member of Advisory Board	10.5yrs	sin datos	sin datos
Olaf Stiller	Chairman of Supervisory Board	14.3yrs	sin datos	sin datos
Peter Wendeln	Deputy Chairman of Supervisory Board	14.3yrs	sin datos	sin datos
Johannes Buchner	Member of Advisory Board	8.3yrs	sin datos	sin datos
Thomas Siklosi	Member of Advisory Board	5.8yrs	sin datos	sin datos
Klaus Rohrig	Member of Supervisory Board	3.4yrs	sin datos	sin datos
Wolfgang Essler	Member of the Supervisory Board	less than a year	sin datos	sin datos

9.2yrs

Permanencia media

Junta con experiencia: La junta directiva de 0W4N se considera experimentada (9.1 años de antigüedad promedio).

Formycon Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Formycon AG Announces Supervisory Board and Executive Changes

Formycon AG Announces Changes to Its Executive Board

Formycon AG, Annual General Meeting, Sep 27, 2021

Recent updates

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

New minor risk - Shareholder dilution

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: €2.62 (vs €1.22 loss in FY 2021)

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021)

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Full year 2021 earnings released: €1.22 loss per share (vs €0.54 loss in FY 2020)

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

First half 2021 earnings released: €0.92 loss per share (vs €0.14 loss in 1H 2020)

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Full year 2020 earnings released

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities

Formycon AG, Annual General Meeting, Sep 27, 2021

Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium

Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab)

Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted

Formycon AG to Report Q1, 2020 Results on Jun 22, 2020

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media